Fed’s Brainard Says Exactly What The Rate Path Looks Like Is Difficult To See Right Now

Live TV – Bloomberg

byBenzinga Newsdesk

November 14, 2022

1 minute read

Live TV – Bloomberg

Credit Suisse Maintains Outperform on Darden Restaurants, Raises Price Target to $180

By vishwanath@benzinga.com

Today, 2:30 AM

Credit Suisse analyst Lauren Silberman maintains Darden Restaurants (NYSE:DRI) with a Outperform and raises the price target from $175 to $180.

DRI

12 Publicly Traded Companies On Fast Company’s ‘Next Big Things In Tech’ List

By Chris Katje

Today, 2:30 AM

Real-world problem solvers are highlighted in the inaugural “Next Big Things In Tech” list by Fast Company. The list included 65 honorees from big companies to start-ups. The names on the list were picked by 14 editors and writers at the magazine.

ADBE

Events
News

NeuBase Therapeutics To Present At Chardan Genetic Medicines Conference Oct. 5 At 11:30 a.m. EDT

By Benzinga Newsdesk

Today, 2:30 AM

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines,

NBSE

Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death

By Vandana Singh

Today, 2:30 AM

Alpine Immune Sciences Inc (NASDAQ:ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and…

ABBV

Fed’s Brainard Says Exactly What The Rate Path Looks Like Is Difficult To See Right Now

Related Posts

Credit Suisse Maintains Outperform on Darden Restaurants, Raises Price Target to $180

12 Publicly Traded Companies On Fast Company’s ‘Next Big Things In Tech’ List

NeuBase Therapeutics To Present At Chardan Genetic Medicines Conference Oct. 5 At 11:30 a.m. EDT

Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death